AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Phosphomannomutase 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q92871

UPID:

PMM1_HUMAN

Alternative names:

PMMH-22

Alternative UPACC:

Q92871; A8K003; Q92586

Background:

Phosphomannomutase 1 (PMM1), also known by its alternative name PMMH-22, plays a pivotal role in cellular processes by being involved in the synthesis of GDP-mannose and dolichol-phosphate-mannose. These compounds are essential for numerous mannosyl transfer reactions. Additionally, PMM1 may have a role in the degradation of glucose-1,6-bisphosphate in ischemic brain conditions, highlighting its importance in metabolic pathways.

Therapeutic significance:

Understanding the role of Phosphomannomutase 1 could open doors to potential therapeutic strategies. Its involvement in critical biochemical pathways suggests that targeting PMM1 could offer new avenues for treating metabolic disorders or managing ischemic brain injuries.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.